Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

ABSTRACT:

Background

Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age.

Methods

We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart.

Results

Solicited adverse events wer

SUBMITTER: Anderson EJ 

PROVIDER: S-EPMC7556339 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature